Charles River (CRL) to Develop RNA-based Therapy With New Pact

Published on 19 Jan 2023 on Zacks via Yahoo Finance

Charles River (CRL) to Develop RNA-based Therapy With New Pact

Charles River Laboratories International, Inc. CRL recently announced viral vector contract development and manufacturing organization (“CDMO”) partnership with Rznomics. Charles River’s viral vector CDMO experience will be utilized by Rznomics to begin clinical development of its RNA-based anticancer gene therapy in liver cancer patients.

The latest partnership will fortify Charles River’s plasmid DNA manufacturing, supporting cell and gene therapy development.

NYSE.AMN price evolution

NYSE.CRL price evolution

NYSE.BSX price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Charles River Laboratories International, Inc.'s (NYSE:CRL) Stock Is Going Strong: Is the Market...

Charles River Laboratories International (NYSE:CRL) has had a great run on the share market with ...

Simply Wall St. via Yahoo Finance 1 Apr 2024

Charles River (CRL) Extends Gene Therapy Offering With New Pact

Charles River Laboratories International, Inc. CRL inked an AAV9 production program deal with Nav...

Zacks via Yahoo Finance 15 Mar 2024

Here's Why You Should Retain Charles River (CRL) Stock Now

Charles River Laboratories International, Inc. CRL is well-poised to grow in the coming quarters,...

Zacks via Yahoo Finance 14 Mar 2024

Insider Sell: CSVP & Chief Accounting Officer Michael Knell Sells Shares of Charles River ...

Charles River Laboratories International Inc (NYSE:CRL), a global provider of essential products ...

GuruFocus.com via Yahoo Finance 12 Mar 2024

Calculating The Fair Value Of Charles River Laboratories International, Inc. (NYSE:CRL)

Key Insights Charles River Laboratories International's estimated fair value is US$328 based on 2...

Simply Wall St. via Yahoo Finance 7 Mar 2024

Insider Sell: EVP & Chief People Officer Victoria Creamer Sells 5,000 Shares of Charles ...

Charles River Laboratories International Inc (NYSE:CRL) has reported an insider sell by Victoria ...

GuruFocus.com via Yahoo Finance 1 Mar 2024

Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2023 Earnings Call Transcript

Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2023 Earnings Call Transcript Februa...

Insider Monkey via Yahoo Finance 15 Feb 2024

John Rogers's Ariel Investment Trims Stake in Resideo Technologies Inc

Overview of John Rogers (Trades, Portfolio)'s Recent Stock Transaction Warning! GuruFocus has det...

GuruFocus.com via Yahoo Finance 15 Feb 2024

John Rogers' Ariel Investment Adjusts Portfolio, Cuts Back on Philip Morris International

Insights from the Latest 13F Filing Reveal Strategic Moves in Q4 2023 John Rogers (Trades, Portfo...

GuruFocus.com via Yahoo Finance 14 Feb 2024

Why Is Charles River Laboratories Stock Trading Higher Today? - Charles River (NYSE:CRL)

Charles River Laboratories International Inc CRL reported fourth-quarter 2023 revenue of $1.01 bi...

Benzinga 14 Feb 2024

News

Charles River (CRL) to Develop RNA-based Therapy With New Pact

NYSE.AMN price evolution

NYSE.CRL price evolution

NYSE.BSX price evolution

Want to become a better investor?